Paige Britt

FDA approves relacorilant for platinum-resistant ovarian cancer, showing significant survival benefits without added safety risks in clinical trials.

FDA approves nivolumab with AVD for Hodgkin lymphoma, showing superior survival rates and reduced toxicity compared to existing treatments.

Phase 2 data show one-time liso-cel CAR T delivers 95% responses in hard-to-treat marginal zone lymphoma, with low severe CRS and neurotoxicity.

FDA clears MyChoice CDx to find HRD-positive advanced ovarian cancer patients for niraparib, using BRCA and genomic instability testing.

COMPASSION-03 follow-up shows cadonilimab delivers durable survival in recurrent/metastatic cervical cancer, including PD‑L1–negative patients.

Denileukin diftitox brings a new systemic option for relapsed CTCL, killing tumor cells and Tregs to boost immunity and expand EU access.

Ipsen pulls Tazverik worldwide after SYMPHONY-1 flags secondary blood cancer risk, halting trials and access programs and moving patients to standard care.

Hi-C on routine FFPE biopsies uncovers hidden lymphoma drivers, enhancer hijacking, and PD-L1 rearrangements, guiding targeted therapy beyond FISH.

Logic-gated CAR T A2B543 enters EVEREST-2 arm 2, adding membrane-tethered IL-12 to boost solid-tumor potency while limiting toxicity.

Clinical trial data show ovarian cancer survival gaps narrow with diverse enrollment, but disparities persist after progression, spotlighting access, toxicity, and care barriers.

Phase 2 data show elenagen plus gemcitabine extends survival in platinum-resistant ovarian cancer with high CA-125, without added toxicity.

RB-1355 reprograms autologous macrophages to heat up lymphoma tumors, avoid lymphodepletion, and deliver fast 1-week cellular therapy.

Electronic symptom reports plus pediatric palliative care improve physical quality of life in advanced childhood cancer when follow-up is consistent.

Screening rates fall as many women seek privacy and convenience; FDA‑cleared home HPV self-sampling may boost access and reduce disparities.

How HRD and BRCA results steer frontline ovarian cancer maintenance—niraparib vs olaparib—plus guidance on recurrence, surgery, and clinic efficiency.

New Uniphar deal widens European managed-access to Lymphir for relapsed CTCL, spotlighting targeted immunotherapy and manageable early-cycle risks.

FDA accepts tirabrutinib for accelerated review in relapsed/refractory CNS lymphoma, spotlighting strong phase 2 responses and a needed U.S. option.

Why most eligible lymphoma patients miss CAR T: experts urge stronger academic-community handoffs, clearer protocols, and smarter caregiver support.

How to manage Richter transformation: rapid biopsy, targeted combos, and early referral for CAR T or transplant, thus closing the access gap.

BTK inhibitors or time-limited venetoclax combos? Expert breaks down CLL frontline choices, IGHV and p53 risk, and what fits patient life.

FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in clinical trials.

Phase 1 data show EB103 delivers 100% complete responses at high dose with manageable toxicity, offering a safer, durable option for high-risk B-cell NHL.

FDA lifts Yescarta limits for relapsed primary CNS lymphoma, expanding CAR T access with phase 1 safety data—what to know about neuro risks.

First-in-human DS3790 trial tests a CD37-targeted ADC for relapsed/refractory B-cell non-Hodgkin lymphoma, aiming to improve response durability and survival.

A recent study reveals significant racial disparities in ovarian cancer trial outcomes, highlighting the urgent need for improved diversity in clinical research.

FDA clears mRNA-based HPV test for primary screening, helping clinicians spot cancer-driving infections, cut overtreatment, and personalize care.

A groundbreaking phase 2 trial explores a novel, chemotherapy-free immunotherapy for relapsed indolent B-cell lymphomas, aiming to enhance patient outcomes.

Gemogenovatucel-T shows remarkable survival benefits in high-risk ovarian cancer patients, highlighting its potential as a new standard of care.

BioInvent's BI-1808 combined with pembrolizumab shows promising antitumor activity in recurrent ovarian cancer, offering hope for better treatment options.